What does the future of breast oncology look like?

In Episode 4, Dr. Jason Mouabbi and Dr. Paolo Tarantino are joined by Professor Giuseppe Curigliano, Professor of Medical Oncology at the University of Milano, Head of the Experimental Therapeutics Program at the European Institute of Oncology, ESMO President-Elect, and Young Science Talent Scout, to forecast the next decade of breast cancer care.

This conversation looks beyond current standards to the next frontier of breast oncology—from the evolution of ADCs and ctDNA to the emerging roles of bispecifics, radioligand therapy, and cancer vaccines.

We’re mapping out where the science is heading and how it will redefine precision medicine in breast cancer!

🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music

#BreastCancer #Oncology #OncologyPodcast #CancerResearch #ClinicalTrials #PrecisionMedicine #MedEd #MedicalOncology #ESMO #CancerInnovation

👉 Cast your vote here: https://www.tinyurl.com/breastfriendsmadness

It’s March Madness, the Breast Friends Madness way!

In Episode 3, Dr. Jason Mouabbi and Dr. Paolo Tarantino are hitting the court to break down the heavy hitters of 2025 using our "Breast Friends Madness" bracket.

Among the featured lineups are studies ranging from the practice-changing results of the DESTINY-Breast trials to the strategic shifts in SERENA-6, monarchE, and ASCENT-04. We’re scouting the data officially rewriting the playbook for HER2+, TNBC, and HR+ care.

EVERY study in this bracket is a WIN for our patients. Let’s get ready to highlight the trials moving the field forward.

▶️ Watch on YouTube

🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox & Amazon Music

#BreastCancer #Oncology #OncologyPodcast #CancerResearch #ClinicalTrials #HER2Positive #TripleNegativeBreastCancer #MedEd #MedicalOncology

What’s coming in 2026 is about to reshape breast oncology.

In Episode 2, Dr. Jason Mouabbi and Dr. Paolo Tarantino go beyond published data to tackle the tough questions about what's next. They break down the evolving landscape of KEYNOTE-756, the rise of oral SERDs in the first line, and the role of HER2DX. From T-DXd in early disease and CNS risk in HER2+, to the promise of improving outcomes in triple-negative breast cancer, they are laying out the roadmap for the future of care.

The landscape is moving fast. Listen in as we prepare for the next wave of practice-changing data.

▶️ Watch on YouTube - https://youtu.be/Skt3jGMBncM

🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox, & Amazon Music

#BreastCancer #Oncology #OncologyPodcast #ClinicalTrials #CancerResearch #HER2Positive #TripleNegative #OralSERD #ADCs #MedicalOncology #MedEd #CancerCare